BR112021021681A2 - Rebamipida para uso na prevenção e/ou tratamento de sinucleinopatias - Google Patents

Rebamipida para uso na prevenção e/ou tratamento de sinucleinopatias

Info

Publication number
BR112021021681A2
BR112021021681A2 BR112021021681A BR112021021681A BR112021021681A2 BR 112021021681 A2 BR112021021681 A2 BR 112021021681A2 BR 112021021681 A BR112021021681 A BR 112021021681A BR 112021021681 A BR112021021681 A BR 112021021681A BR 112021021681 A2 BR112021021681 A2 BR 112021021681A2
Authority
BR
Brazil
Prior art keywords
rebamipide
prevention
treatment
synucleinopathies
synucleinopathy
Prior art date
Application number
BR112021021681A
Other languages
English (en)
Inventor
Ivan Danek
Original Assignee
Square Power Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Square Power Ltd filed Critical Square Power Ltd
Publication of BR112021021681A2 publication Critical patent/BR112021021681A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

rebamipida para uso na prevenção e/ou tratamento de sinucleinopatias. a presente invenção refere-se à rebamipida para o uso em um método de prevenção e/ou tratamento de uma sinucleinopatia, em particular, de doença de parkinson. em particular, a rebamipida é usada na prevenção e/ou tratamento de uma sinucleinopatia em uma pessoa que sofre de permeabilidade intestinal aumentada ou em uma pessoa que está em risco de permeabilidade intestinal aumentada.
BR112021021681A 2019-04-30 2020-04-30 Rebamipida para uso na prevenção e/ou tratamento de sinucleinopatias BR112021021681A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19020318.2A EP3741370A1 (en) 2019-04-30 2019-04-30 Rebamipide for use in prevention and/or treatment of synucleinopathies
PCT/EP2020/062120 WO2020221892A2 (en) 2019-04-30 2020-04-30 Rebamipide for use in prevention and/or treatment of synucleinopathies

Publications (1)

Publication Number Publication Date
BR112021021681A2 true BR112021021681A2 (pt) 2021-12-21

Family

ID=66396957

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021681A BR112021021681A2 (pt) 2019-04-30 2020-04-30 Rebamipida para uso na prevenção e/ou tratamento de sinucleinopatias

Country Status (12)

Country Link
US (1) US20220202805A1 (pt)
EP (1) EP3741370A1 (pt)
JP (1) JP2022533005A (pt)
KR (1) KR20220003064A (pt)
CN (1) CN113784715A (pt)
AU (1) AU2020266279A1 (pt)
BR (1) BR112021021681A2 (pt)
CA (1) CA3138389A1 (pt)
EA (1) EA202192961A1 (pt)
MX (1) MX2021013360A (pt)
WO (1) WO2020221892A2 (pt)
ZA (1) ZA202110052B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112603899A (zh) * 2020-12-23 2021-04-06 南京友杰医药科技有限公司 瑞巴派特肠溶片及其制备方法

Also Published As

Publication number Publication date
JP2022533005A (ja) 2022-07-21
WO2020221892A2 (en) 2020-11-05
ZA202110052B (en) 2023-11-29
AU2020266279A1 (en) 2021-12-23
WO2020221892A3 (en) 2020-12-24
EP3741370A1 (en) 2020-11-25
CA3138389A1 (en) 2020-11-05
EA202192961A1 (ru) 2022-01-20
US20220202805A1 (en) 2022-06-30
KR20220003064A (ko) 2022-01-07
MX2021013360A (es) 2022-01-31
CN113784715A (zh) 2021-12-10

Similar Documents

Publication Publication Date Title
BR112017008093A2 (pt) processos para tratamento de doenças oculares
MX2018010693A (es) Compuestos biciclicos para diagnostico y terapia.
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
BR112018069515A2 (pt) uso de masitinibe para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica
BR112018014675A2 (pt) novos derivados de cianoindolina substituída como inibidores de nik
SG11201903725UA (en) Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
EP4285993A3 (en) Growth differentiation factor 15 as biomarker for metformin
BR112017025998A2 (pt) inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit
BR112021021826A8 (pt) Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
BR112021018262A2 (pt) Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina
BR112021021681A2 (pt) Rebamipida para uso na prevenção e/ou tratamento de sinucleinopatias
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR112019008241A2 (pt) tratamento do prurigo nodular
NO20073104L (no) Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser
MX2020013100A (es) Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.
BR112022003918A2 (pt) Rebamipida para uso na prevenção e tratamento da doença de crohn
BR112022019168A2 (pt) Tratamento de distúrbios respiratórios
MX2022000783A (es) Inhibidores de la ferroportina para el uso en la prevencion y el tratamiento de lesiones renales.
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
BR112017027298A2 (pt) método de tratamento e/ou prevenção de drea ou asma em pacientes humanos; e método de prevenção, reversão ou tratamento de sintoma(s) de dessensibilização à aspirina em pacientes com drea
MX2022002625A (es) Rebamipida para usarse en la profilaxis y tratamiento de enfermedad celiaca.
CL2021003602A1 (es) Métodos para tratar o prevenir la atrofia muscular espinal